Literature DB >> 12689929

IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL.

Jose L Moreno1, Michele Kaczmarek, Achsah D Keegan, Mehrdad Tondravi.   

Abstract

Numerous reports have described the effects of interleukin-4 (IL-4) on bone biology. Previous studies, performed using complex coculture systems, demonstrated the effects of IL-4 on osteoblasts and osteoclasts. To directly test the effect of IL-4 on osteoclasts, we took advantage of a simplified system using recombinant receptor activator of nuclear factor kappaB ligand (RANKL) as the osteoclast differentiation factor. We analyzed the ability of IL-4 to directly regulate osteoclast differentiation and mature osteoclast function. We found that IL-4 inhibited the differentiation of osteoclasts from bone marrow precursors in an irreversible manner and also inhibited the resorptive capacity of mature osteoclasts. In the presence of IL-4, we detected the appearance of tartrate-resistant acid phosphatase (TRAP)-negative multinucleated giant (MNG) cells. Both IL-4 effects were dependent on signal transducer and activator of transcription 6 (STAT6). We found that IL-4 suppresses RANK mRNA expression in the developing precursor cells. When RANK was ectopically expressed under the cytomegalovirus (CMV) promoter in RAW264.7 macrophages, IL-4 treatment did not inhibit osteoclast development. Furthermore, when osteoclastogenesis was induced independently of RANKL by using tumor necrosis factor-alpha (TNF-alpha), IL-4 inhibited osteoclast differentiation through a STAT6-dependent mechanism. These results suggest that IL-4 regulates osteoclast development by regulating gene expression, including RANK. We propose that IL-4 irreversibly regulates the lineage commitment of precursor cells by regulating gene expression, resulting in the suppression of osteoclast development and the generation of MNG cells as an alternative pathway of differentiation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12689929     DOI: 10.1182/blood-2002-11-3437

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  TLR2 signaling and Th2 responses drive Tannerella forsythia-induced periodontal bone loss.

Authors:  Srinivas R Myneni; Rajendra P Settem; Terry D Connell; Achsah D Keegan; Sarah L Gaffen; Ashu Sharma
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

2.  The paired-box homeodomain transcription factor Pax6 binds to the upstream region of the TRAP gene promoter and suppresses receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation.

Authors:  Masakazu Kogawa; Koji Hisatake; Gerald J Atkins; David M Findlay; Yuichiro Enoki; Tsuyoshi Sato; Peter C Gray; Yukiko Kanesaki-Yatsuka; Paul H Anderson; Seiki Wada; Naoki Kato; Aya Fukuda; Shigehiro Katayama; Masafumi Tsujimoto; Tetsuya Yoda; Tatsuo Suda; Yasushi Okazaki; Masahito Matsumoto
Journal:  J Biol Chem       Date:  2013-08-29       Impact factor: 5.157

3.  Interleukin-4 inhibits RANKL-induced NFATc1 expression via STAT6: a novel mechanism mediating its blockade of osteoclastogenesis.

Authors:  Jing Cheng; Jianzhong Liu; Zhenqi Shi; Duorong Xu; Shaokai Luo; Gene P Siegal; Xu Feng; Shi Wei
Journal:  J Cell Biochem       Date:  2011-11       Impact factor: 4.429

Review 4.  The multiple faces of autoimmune-mediated bone loss.

Authors:  Georg Schett; Jean-Pierre David
Journal:  Nat Rev Endocrinol       Date:  2010-11-02       Impact factor: 43.330

Review 5.  Osteoimmunology: interactions of the bone and immune system.

Authors:  Joseph Lorenzo; Mark Horowitz; Yongwon Choi
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

6.  NF-κB signaling participates in both RANKL- and IL-4-induced macrophage fusion: receptor cross-talk leads to alterations in NF-κB pathways.

Authors:  Minjun Yu; Xiulan Qi; Jose L Moreno; Donna L Farber; Achsah D Keegan
Journal:  J Immunol       Date:  2011-07-06       Impact factor: 5.422

7.  Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity.

Authors:  Hiroya Hasegawa; Seisui Kido; Mineko Tomomura; Kengo Fujimoto; Michi Ohi; Masaru Kiyomura; Haruhide Kanegae; Akemi Inaba; Hiroshi Sakagami; Akito Tomomura
Journal:  J Biol Chem       Date:  2010-06-14       Impact factor: 5.157

Review 8.  The emerging field of osteoimmunology.

Authors:  Kofi A Mensah; Jie Li; Edward M Schwarz
Journal:  Immunol Res       Date:  2009-01-30       Impact factor: 2.829

9.  IL-4 and IL-13 inhibit IL-1β and TNF-α induced kinin B1 and B2 receptors through a STAT6-dependent mechanism.

Authors:  P P C Souza; A B Brechter; R I Reis; C A S Costa; P Lundberg; U H Lerner
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

Review 10.  Osteoimmunology: cytokines and the skeletal system.

Authors:  Seoung-Hoon Lee; Tae-Soo Kim; Yongwon Choi; Joseph Lorenzo
Journal:  BMB Rep       Date:  2008-07-31       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.